Brought to you by 
Vertex nets $390.1mm through sale of common shares and debt
26 Feb 2008
Executive Summary
Vertex Pharmaceuticals (infectious and immune diseases and cancer) has netted $112.1mm through the follow-on public offering of 6.9mm common shares (including the overallotment) at $17.14. The company also concurrently netted $278.5mm by selling 4.75% five-year convertible senior subordinated notes which convert into 43.22 common shares per $1k in notes (about $23.14 per share).
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Financing
- Convertible Debt
- FOPO
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Vertex nets $390.1mm through sale of common shares and debt
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice